MC

706.7

-0.42%↓

ALV

258.1

+0.7%↑

SAF

200.8

-0.89%↓

BBVA

9.216

+0.46%↑

BN

59

-0.47%↓

MC

706.7

-0.42%↓

ALV

258.1

+0.7%↑

SAF

200.8

-0.89%↓

BBVA

9.216

+0.46%↑

BN

59

-0.47%↓

MC

706.7

-0.42%↓

ALV

258.1

+0.7%↑

SAF

200.8

-0.89%↓

BBVA

9.216

+0.46%↑

BN

59

-0.47%↓

MC

706.7

-0.42%↓

ALV

258.1

+0.7%↑

SAF

200.8

-0.89%↓

BBVA

9.216

+0.46%↑

BN

59

-0.47%↓

MC

706.7

-0.42%↓

ALV

258.1

+0.7%↑

SAF

200.8

-0.89%↓

BBVA

9.216

+0.46%↑

BN

59

-0.47%↓

Search

Bayer AG

Geschlossen

Branche Finanzen

26.14 0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

26.085

Max

26.41

Schlüsselkennzahlen

By Trading Economics

Einkommen

663M

2B

Verkäufe

1.9B

14B

KGV

Branchendurchschnitt

30.837

24.864

EPS

2.82

Dividendenrendite

4.737

Gewinnspanne

14.524

EBITDA

1.3B

4.4B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+12.71 upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.74%

4.45%

Nächstes Ergebnis

6. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.5B

27B

Vorheriger Eröffnungskurs

25.99

Vorheriger Schlusskurs

26.14

Nachrichtenstimmung

By Acuity

38%

62%

75 / 457 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Bayer AG Chart

Ähnliche Nachrichten

14. Mai 2024, 13:21 UTC

Ergebnisse

Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update

14. Mai 2024, 06:13 UTC

Ergebnisse

Bayer Net Profit Falls on Lower Sales, Currency Headwinds

2. Mai 2024, 11:10 UTC

Wichtige Markttreiber

Bayer Shares Surge After Monsanto Appeal Win

5. März 2024, 09:09 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bayer Decides Against Splitting Into Separate Units for Now -- 2nd Update

5. Juni 2024, 09:57 UTC

Heiße Aktien

Stocks to Watch Wednesday: CrowdStrike, HPE, Dollar Tree -- WSJ

14. Mai 2024, 11:00 UTC

Market Talk
Ergebnisse

Bayer Earnings Show Progression on Turnaround Strategy -- Market Talk

14. Mai 2024, 05:34 UTC

Ergebnisse

Bayer Backs 2024 Currency-Adjusted Outlook

14. Mai 2024, 05:32 UTC

Ergebnisse

Bayer: Analysts Saw 1Q Ebitda Before Special Items at EUR4.15B

14. Mai 2024, 05:32 UTC

Ergebnisse

Bayer 1Q Ebitda Before Special Items EUR4.41B

14. Mai 2024, 05:32 UTC

Ergebnisse

Bayer 1Q EPS EUR2.04

14. Mai 2024, 05:32 UTC

Ergebnisse

Bayer: Analysts Saw 1Q Sales at EUR14.08B

14. Mai 2024, 05:32 UTC

Ergebnisse

Bayer 1Q Sales EUR13.77B

14. Mai 2024, 05:31 UTC

Ergebnisse

Bayer 1Q EBIT EUR3.09B

14. Mai 2024, 05:31 UTC

Ergebnisse

Bayer: Analysts Saw 1Q Net Pft at EUR1.73B

14. Mai 2024, 05:31 UTC

Ergebnisse

Bayer 1Q Net Pft EUR2B

13. Mai 2024, 13:26 UTC

Ergebnisse

Bayer Investors Brace for Long Turnaround -- Talking Markets

15. Apr. 2024, 14:01 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk

15. Apr. 2024, 13:39 UTC

Market Talk

Bayer's Debt Reduction, Litigation and Drug Pipeline in Focus at 1Q Results -- Market Talk

22. März 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ -2-

22. März 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ

5. März 2024, 10:23 UTC

Ergebnisse

Bayer CEO Was Speaking on Call After Earnings

5. März 2024, 10:19 UTC

Market Talk
Ergebnisse

Bayer's EPS Guidance Implies Consensus Downgrades -- Market Talk

5. März 2024, 09:55 UTC

Market Talk
Ergebnisse

Bayer's 2024 Guidance Is Below Expectations -- Market Talk

5. März 2024, 09:44 UTC

Ergebnisse

Bayer CEO: Time it Takes For Major Structural Change is Time We Don't Have, Need to Focus on Challenges

5. März 2024, 09:44 UTC

Ergebnisse

Bayer CEO: There Has Been Calls From Major Shareholders For Break-Up, But They Understand Associated Drawbacks

5. März 2024, 08:52 UTC

Ergebnisse

Bayer CEO: Exploring All Avenues to Remove Litigation Completely

5. März 2024, 08:51 UTC

Ergebnisse

Bayer CEO: Strategy of Defence Against Litigation is Not Enough

5. März 2024, 08:44 UTC

Ergebnisse

Bayer CEO: Need Total Focus on Overcoming Challenges

5. März 2024, 08:44 UTC

Ergebnisse

Bayer CEO: Separation of Consumer Health Would Remove Steady Cash Flowing Business, Valutions Not Great

5. März 2024, 08:43 UTC

Ergebnisse

Bayer CEO: IPO or Spin Would Require All-Hands on Deck For Long Period

Peer-Vergleich

Kursveränderung

Bayer AG Prognose

Kursziel

By TipRanks

12.71% Vorteil

12-Monats-Prognose

Durchschnitt 30.5 EUR  12.71%

Hoch 34 EUR

Tief 28 EUR

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bayer AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

1

Buy

11

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 28.335Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

75 / 457 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non